Background: The canonical Wnt signaling pathway plays important roles in cellular proliferation and differentiation, axonal outgrowth, cellular maintenance in retinas. Here we test the hypothesis that elements of the Wnt signaling pathway are involved in the regulation of eye growth and prevention of myopia, in the mouse form-deprivation myopia model.
Methodology/principal Findings: (1) One hundred twenty-five C57BL/6 mice were randomly distributed into form-deprivation myopia and control groups. Form-deprivation myopia (FDM) was induced by suturing the right eyelid, while the control group received no treatment. After 1, 2, and 4 weeks of treatment, eyes were assessed in vivo by cycloplegic retinoscopic refraction and axial length measurement by photography or A-scan ultrasonography. Levels of retinal Wnt2b, Fzd5 and β-catenin mRNA and protein were evaluated using RT-PCR and western blotting, respectively. (2) Another 96 mice were divided into three groups: control, drugs-only, and drugs+FDM (by diffuser). Experimentally treated eyes in the last two groups received intravitreal injections of vehicle or the proteins, DKK-1 (Wnt-pathway antagonist) or Norrin (Wnt-pathway agonist), once every three days, for 4 injections total. Axial length and retinoscopic refraction were measured on the 14th day of form deprivation. Following form-deprivation for 1, 2, and 4 weeks, FDM eyes had a relatively myopic refractive error, compared with contralateral eyes. There were no significant differences in refractive error between right and left eye in control group. The amounts of Wnt2b, Fzd5 and β-catenin mRNA and protein were significantly greater in form-deprived myopia eyes than in control eyes.DKK-1 (antagonist) reduced the myopic shift in refractive error and increase in axial elongation, whereas Norrin had the opposite effect in FDM eyes.
Conclusions/significance: Our studies provide the first evidence that the Wnt2b signaling pathway may play a role in the development and progression of form-deprivation myopia, in a mammalian model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995642 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091086 | PLOS |
Exp Eye Res
December 2024
Department of Preventative Ophthalmology, Shanghai Eye Disease Prevention and Treatment Center, Shanghai Eye Hospital, Shanghai, China. Electronic address:
Myopia is a significant global public health issue. Key interventions for managing myopia include atropine treatment, optical correction, and surgical methods. This study focused on evaluating alterations in retinal protein expression after atropine therapy for myopia.
View Article and Find Full Text PDFExp Eye Res
December 2024
Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
BMC Ophthalmol
November 2024
Ophthalmology Department of Affiliated Hospital of North Sichuan Medical College, Medical School of Ophthalmology & Optometry, Nanchong, Sichuan Province, 637000, China.
Front Physiol
October 2024
Department of Ophthalmology and Clinical Center of Optometry, Peking University People's Hospital, Beijing, China.
Medicine (Baltimore)
October 2024
Department of Children's Massage Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Myopia is the most common refractive error worldwide, contributing not only to visual impairment but also serving as a potential risk factor for various severe ocular diseases. Its impact on patients' quality of life and health is significant and imposes substantial socioeconomic burdens. In this study, we analyzed the top 100 most cited articles related to myopia published in the Web of Science Core Collection database from January 2000 to February 2024.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!